{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-007235","form_type":"8-K","ticker":"LAB","cik":"0001162194","company_name":"STANDARD BIOTOOLS INC.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.775126+00:00","generated_at":"2026-06-22T02:56:12.879602+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Standard BioTools Q3 core revenue up 30% sequentially to $24.8M; GAAP net loss $29.4M","bullets":["Core product/services revenue $24.8M, +30% sequentially; total revenue $25.6M, down from $28.5M YoY.","GAAP net loss $29.4M vs $13.8M in Q3 2021; non-GAAP net loss $20.8M vs $5.4M.","Cash, equivalents & short-term investments $185.2M at Sept 30, down from $211.2M at June 30.","First restructuring phase saves $8M annually; reiterates 65-68% non-GAAP gross margin goal by end of 2023.","Aiming for positive free cash flow by year-end 2024; launched X9 Real-Time PCR System."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-007235","json":"https://secwatch.observer/filing/0001171843-22-007235.json","markdown":"https://secwatch.observer/filing/0001171843-22-007235.md","text":"https://secwatch.observer/filing/0001171843-22-007235.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1162194/000117184322007235/0001171843-22-007235-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1162194/000117184322007235/f8k_110822.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T02:56:12.879602+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e22cad3bd85743f19a56c51599b649020f866c07","claim":"STANDARD BIOTOOLS INC. reported financial results for third quarter ended September 30, 2022.","evidence_excerpt":"On November 8, 2022, Standard BioTools Inc. (the “Company”) issued a press release reporting its financial results for the third fiscal quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1162194/000117184322007235/0001171843-22-007235-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}